KALA BIO, Inc. (NASDAQ:KALA) Given Consensus Rating of “Hold” by Analysts

Shares of KALA BIO, Inc. (NASDAQ:KALA) have been given an average rating of “Hold” by the six research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $20.3750.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of KALA BIO in a report on Monday, December 29th.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in KALA. Virtu Financial LLC purchased a new stake in KALA BIO during the 4th quarter worth about $48,000. XTX Topco Ltd purchased a new position in KALA BIO during the 2nd quarter valued at about $62,000. Jane Street Group LLC bought a new stake in shares of KALA BIO during the fourth quarter valued at about $80,000. Geode Capital Management LLC increased its position in shares of KALA BIO by 2.8% during the second quarter. Geode Capital Management LLC now owns 56,367 shares of the company’s stock valued at $268,000 after buying an additional 1,534 shares during the period. Finally, Baker BROS. Advisors LP lifted its holdings in shares of KALA BIO by 83.1% in the fourth quarter. Baker BROS. Advisors LP now owns 1,804,055 shares of the company’s stock worth $1,003,000 after buying an additional 818,962 shares in the last quarter. Hedge funds and other institutional investors own 24.61% of the company’s stock.

KALA BIO Price Performance

NASDAQ KALA opened at $0.20 on Friday. The business’s fifty day moving average is $0.40 and its 200-day moving average is $2.45. The stock has a market capitalization of $182.27 million, a price-to-earnings ratio of -0.03 and a beta of -2.37. KALA BIO has a one year low of $0.20 and a one year high of $20.60.

About KALA BIO

KALA Bio (NASDAQ: KALA) is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for ocular diseases. The company’s proprietary surface charge–based nanoparticle delivery platform is designed to enhance penetration and retention of therapeutic agents on the ocular surface. This technology is the basis for its lead product, Eysuvis (KPI-121 1.0%), an FDA-approved topical corticosteroid for short-term relief of ocular itching associated with allergic conjunctivitis.

Beyond its approved therapy, KALA Bio is advancing a pipeline of investigational drug candidates targeting inflammatory and degenerative eye conditions.